Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

546.66 +4.83 (+0.89%)
Streaming Delayed Price Updated: 3:48 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks. 
Via InvestorPlace
News headline image
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics ↗
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Expert Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
News headline image
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
The Latest Analyst Ratings For United Therapeutics ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock ↗
 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Double Your Money in the Next 24 Months ↗
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
News headline image
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity ↗
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge. 
Via Benzinga
News headline image
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases. ↗
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
News headline image
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
News headline image
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor ↗
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look. 
Via InvestorPlace
News headline image
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024 ↗
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year. 
Via InvestorPlace
News headline image
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making ↗
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
News headline image
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
News headline image
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings ↗
Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial... 
Via Benzinga
News headline image
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.